Hypertonic saline creates an osmotic pressure that increases the volume of airway surface liquid, restore mucus clearance, and improve lung function.
Recent clinical studies in patients with cystic fibrosis, have shown that inhalation of hypertonic saline produced a sustained acceleration of mucus clearance and improved lung function. This treatment improves sputum viscosity and ease expectoration.
The advantages of treatment with 7% hypertonic saline in lung diseases are:
- Improving lung function
- Stimulate mucociliary clearance
- Improving quality of life
- Decreases hospital admissions
- Safe
- Inexpensive
- Effective treatment of moderately and severe lung diseases.
Presentation: 24 single use containers of 5ml. Regulatory Status: CE Class IIa Sterile Medical Device.
References:
- Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis Fiona Kellett a,*, Niven M. Robert Respiratory Medicine (2011) 105, 1831e1835.
- H Pelletier AJ, Mansbach JM, Camargo CA Jr. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics.2006;118(6):2418-2423.
- Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446.
- Viswanathan M, King VJ, Bordley C, et al. Management of bronchiolitis in infants and children. Evid Rep Technol Assess (Summ). 2003;69(69):1-
- Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am Rev Respir Dis 1978; 117: 199–203.
- Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PTP. Effect of hypertonic saline, amiloride and cough on mucociliary clearance in patientswith cystic fibrosis. A J Respir Crit Care Med 1996; 153.
- Smith CM. The role of osmotic stimuli in the provocation of asthma. PhD Thesis 1988, University of Sydney, Australia.
- Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis Fiona Kellett a,*, Niven M. Robert Respiratory Medicine (2011) 105, 1831e1835.